Skip to content
TheChatArchiveThe Chat Archive
Kimikimi-k2-0711-preview· Moonshot AIHugging Face LMArena Human Preference 140K

Give me 3 stocks idea that are likely to deliver at last 20% gains in the next 12 months…

From a Chatbot Arena battleThe same person sent this prompt to two anonymous models at once. Compare it with grok-4-0709’s answer.
  1. User

    Give me 3 stocks idea that are likely to deliver at last 20% gains in the next 12 months and present least risk

  2. Kimi Assistant

    Here are three large-cap, high-quality names that combine (1) visible catalysts, (2) durable competitive moats, and (3) balance-sheet strength—so the downside is limited even if the macro picture softens. Each has a credible path to ≥20 % upside over the next 12 months, based on consensus estimates and recent management guidance.

    1. Alphabet Inc. (GOOGL)
      • Catalyst: Generative-AI monetization is moving from “experiment” to revenue. Search Generative Experience (SGE) and Performance Max campaigns are already lifting click-through rates and pricing. Cloud growth is re-accelerating (Q1 +28 % y/y), and YouTube Shorts now monetizes at >15bnannualrun−rate.•Valuation:19×forwardEPSex−cash—roughlya2515 bn annual run-rate. • Valuation: 19× forward EPS ex-cash—roughly a 25 % discount to the S&P 500 despite faster growth and 30 % FCF margins. A simple 22× multiple on 2025 EPS (~8.00) gives a 175–175–180 target vs. ~145today.•Downsideprotection:145 today. • Downside protection: 110 bn in gross cash, dominant search share, and a $70 bn buy-back authorization.

    2. Eli Lilly & Co. (LLY)
      • Catalyst: Mounjaro / Zepbound for obesity and diabetes is tracking well ahead of scripts for any prior drug launch. Management raised 2024 revenue guidance twice already; peak sales estimates keep moving up (Street now ~55bnacrossdiabetes+obesity).Alzheimer’sdrugdonanemabPDUFAdateis24Feb2025—approvaladdsanothermulti−billionfranchise.•Valuation:29×2025EEPS,butEPSiscompounding>3055 bn across diabetes + obesity). Alzheimer’s drug donanemab PDUFA date is 24 Feb 2025—approval adds another multi-billion franchise. • Valuation: 29× 2025E EPS, but EPS is compounding >30 % through 2027. A modest multiple re-rating to 32× on 2025 EPS (~18) implies a 575–575–600 stock vs. ~$480 today.
      • Downside protection: Patent cliffs are 10+ years away; balance sheet is net-cash post-recent bond raise.

    3. JPMorgan Chase & Co. (JPM)
      • Catalyst: Net-interest income (NII) troughed in Q1 and is now inflecting higher as the Fed pivots toward rate cuts (lower deposit betas, securities book re-pricing). Investment-banking fees are rebounding (Q1 IB revenue +21 % y/y), and credit costs remain benign (NCO ratio 0.49 %). Stress-test results in June should free up additional capital for buy-backs.
      • Valuation: 11.5× 2025 EPS and 1.4× tangible book—both 1 std-dev below 10-yr averages. A 13× multiple on 2025 EPS (17.50)givesa17.50) gives a 225–230targetvs. 230 target vs. ~195 today.
      • Downside protection: #1 deposit share, fortress balance sheet (CET1 15 %), and a 2.5 % dividend yield that grows every year.

    Risk summary
    All three are mega-caps with diversified revenue bases and strong balance sheets, so the primary risks are macro (recession, rates) rather than company-specific. Position sizing and a 12-month horizon are key—none of these names is immune to a broad market draw-down, but their fundamental momentum and valuation cushions make a 20 % gain a realistic base case.

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.